Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR

Abstract

Studies have proved that microRNA-101 (miR-101) functions as a tumor suppressor and is associated with growth and apoptosis of various human cancers. However, the role of miR-101 in osteosarcoma and the possible mechanism by which miR-101 affects the tumor growth and apoptosis have not been fully elucidated. In this study, we found that the expression of miR-101 was down-regulated in osteosarcoma tissues and Saos-2 cell line as compared with that in adjacent non-neoplastic bone tissues and the osteoblastic cell line. To better characterize the role of miR-101 in osteosarcoma, we used a gain-of-function analysis by transfecting human osteosarcoma cell line Saos-2 with chemically synthesized miR-101 mimics. The results showed that overexpression of miR-101 inhibited the proliferation and promoted the apoptosis of Saos-2 cells. Meanwhile, bioinformatic analysis demonstrated that mTOR gene was a direct target of miR-101. Overexpression of miR-101 significantly decreased the expression of mTOR at both mRNA and protein levels in Saos-2 cells, consequently inhibiting Saos-2 cells proliferation and promoting cells apoptosis in an mTOR-dependent manner. Taken together, these data suggest that miR-101 may act as a tumor suppressor, which is commonly downregulated in both osteosarcoma tissues and cells. mTOR plays an important role in mediating miR-101 dependent biological functions in osteosarcoma. Reintroduction of miR-101 may be a novel therapeutic strategy by down-regulating mTOR expression.

Keywords

miR-101 / mTOR / osteosarcoma / proliferation / apoptosis

References

[1] KobayashiE, HornicekFJ, DuanZ. MicroRNA involvement in osteosarcoma. Sarcoma, 2012, 2012: 359739 PMCID: 3329862 PMID: 22550419

[2] GellerDS, GorlickR. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol, 2010, 8(10): 705-718 PMID: 21317869

[3] MaO, CaiWW, ZenderL, et al. . MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res, 2009, 69(6): 2559-2567 PMCID: 2663905 PMID: 19276372

[4] BielackSS, Kempf-BielackB, DellingG, et al. . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002, 20(3): 776-790 PMID: 11821461

[5] OttavianiG, JaffeN. The epidemiology of osteosarcoma. Cancer Treat Res, 2009, 152: 3-13 PMID: 20213383

[6] AmbrosV. microRNAs: tiny regulators with great potential. Cell, 2001, 107(7): 823-826 PMID: 11779458

[7] VolkN, ShomronN. Versatility of microRNA biogenesis. PLoS One, 2011, 6(5): e19391 PMCID: 3091858 PMID: 21572999

[8] YanK, GaoJ, YangT, et al. . MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One, 2012, 7(3): e33778 PMCID: 3310405 PMID: 22457788

[9] FanL, WuQ, XingX, et al. . MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Chinese), 2012, 44(5): 407-414

[10] HuZ, LinY, ChenH, et al. . MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun, 2013, 435(1): 82-87 PMID: 23618864

[11] ZhangY, GuoX, XiongL, et al. . MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett, 2012, 586(24): 4362-4370 PMID: 23178713

[12] HuangF, LinC, ShiYH, et al. . MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells. Asian Pac J Cancer Prev, 2013, 14(10): 5915-5920 PMID: 24289600

[13] YinJ, WangM, JinC, et al. . miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett, 2014, 7(2): 461-465 PMCID: 3881938 PMID: 24396470

[14] XuY, AnY, WangY, et al. . miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep, 2013, 29(5): 2019-2024 PMID: 23483142

[15] WangR, WangHB, HaoCJ, et al. . MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One, 2012, 7(10): e46173 PMCID: 3469601 PMID: 23071542

[16] FasoloA, SessaC. Targeting mTOR pathways in human malignancies. Curr Pharm Des, 2012, 18(19): 2766-2777 PMID: 22475451

[17] ZhaoL, TengB, WenL, et al. . mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma. Int J Clin Exp Med, 2014, 7(2): 337-347 PMCID: 3931586 PMID: 24600487

[18] MarioniG, StaffieriA, LoraL, et al. . mTOR expression and prognosis in elderly patients with laryngeal carcinoma: uni- and multi-variate analyses. Oral Oncol, 2012, 48(6): 530-534 PMID: 22285859

[19] ZhangB, PanX, CobbGP, et al. . microRNAs as oncogenes and tumor suppressors. Dev Biol, 2007, 302(1): 1-12 PMID: 16989803

[20] MedinaPP, NoldeM, SlackFJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010, 467(7311): 86-90 PMID: 20693987

[21] KongW, HeL, CoppolaM, et al. . MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem, 2010, 285(23): 17 869-17 879

[22] CostineanS, ZanesiN, PekarskyY, et al. . Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA, 2006, 103(18): 7024-7029 PMCID: 1459012 PMID: 16641092

[23] ChandramouliA, OnyeaguchaBC, Mercado-PimentelME, et al. . MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther, 2012, 13(3): 175-183 PMCID: 3336073 PMID: 22353936

[24] ZhangJG, GuoJF, LiuDL, et al. . MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol, 2011, 6(4): 671-678 PMID: 21270667

[25] ChenK, FanW, WangX, et al. . MicroRNA-101 mediates the suppressive effect of laminar shear stress on mTOR expression in vascular endothelial cells. Biochem Biophys Res Commun, 2012, 427(1): 138-142 PMID: 22989749

[26] LaplanteM, SabatiniDM. mTOR signaling in growth control and disease. Cell, 2012, 149(2): 274-293 PMCID: 3331679 PMID: 22500797

[27] GobinB, BattagliaS, LanelR, et al. . NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett, 2014, 344(2): 291-298 PMID: 24333720

[28] GrabinskiN, EwaldF, HofmannBT, et al. . Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer, 2012, 11: 85 PMCID: 3545733 PMID: 23167739

[29] LiM, SunH, SongL, et al. . Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncol Lett, 2012, 4(6): 1213-1218 PMCID: 3506752 PMID: 23205120